Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion
Details : Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.
Brand Name : Tuznue
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 31, 2024
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ulenistamab,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PBP1510 (ulenistamab) targets pancreatic adenocarcinoma upregulated factor, a tumour-specific protein, found to be overexpressed in majority of pancreatic cancer cases. It represents a promising therapeutic strategy for addressing the unmet medical needs...
Brand Name : PBP1510
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 21, 2023
Lead Product(s) : Ulenistamab,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Prestige Biopharma Submitted Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar
Details : Tuznue (trastuzumab) targets HER2, which is overexpressed in some types of cancer cells and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.
Brand Name : Tuznue
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2022
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Prestige´s bevacizumab (HD204) is a mAb biosimilar to Roche’s Avastin®, an inhibitor of vascular endothelial growth factor (VEGF), which is used in combination with other therapies to treat patients with multiple forms of cancer.
Brand Name : HD20
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PBP1510,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PBP1510 (ulenistamab), a first-in-class anti-PAUF monoclonal antibody,is envisioned to provide significant benefit to all patients affected by PAUF-positive pancreatic cancer.
Brand Name : PBP1510
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 27, 2022
Lead Product(s) : PBP1510,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Covax-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Vaxine
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/inf...
Brand Name : Spikogen
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Covax-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Vaxine
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.
Brand Name : Troika
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 14, 2022
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PBP1510,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical data of PBP1510 presented in the poster shows notable regression in tumour volume and weight in subcutaneous as well as orthotopic patient derived cancer xenograft (PDX) mouse models treated with PBP1510 compared to gemcitabine and IgG contro...
Brand Name : PBP1510
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 08, 2022
Lead Product(s) : PBP1510,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trastuzumab,Docetaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be responsible for local registrations, marketing and sales in the...
Brand Name : HD201
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 09, 2021
Lead Product(s) : Trastuzumab,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Prestige Bio Receives French Ansm Approval for Phase 1/2a Trial of PBP1510
Details : French National Agency for the Safety of Medicines and Health Products (L'Agence nationale de sécurité du medicament, ANSM) has approved a phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of panc...
Brand Name : PBP1510
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 22, 2021
LOOKING FOR A SUPPLIER?